TEVA ▼ -1.3% - Teva Pharmaceutical Industries Limited $TEVA Goldman Sachs raised the firm's price target on Teva to $55 from $50 and keeps a Buy rating on the shares. Austedo sales are expected to face near-term volatility from inventory reductions and IRA-negotiated Medicare pricing in 2027, but these headwinds are viewed as well understood, with management reaffirming its $2.5B+ FY27 target and sales expected to bottom in 1Q27 before returning to growth, while the company's long-term earnings outlook remains intact, the analyst tells investors in a research note. 04-NOV-2026 07:30 AM ET